May 24th 2023
Bill 1196 / Assembly Bill 1673 aims to improve access to precision medicine for patients with cancer in New York by requiring all state-regulated health plans to cover biomarker testing when it is supported by medical and scientific evidence.
Expert Explains the Importance of Genetic Testing for Patients With Ovarian Cancer
March 14th 2017During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD, offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing.
Read More
Molecular Profiling on the Uptake for Increased Targeted Therapies in Bladder Cancer
November 3rd 2016The recommendation for molecular testing made in the second revision of the 2016 guidelines on bladder cancer from the National Comprehensive Cancer Network (NCCN) could make a considerable difference in increasing the amount of trials and targeted therapies in the long run for subtypes of patients with bladder cancer.
Read More
Novel TKI Examined in Metastatic Breast Cancer Patients with HER2 Mutation
June 8th 2016Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.
Read More
Next-Generation Sequencing in Contralateral Breast Cancer Could Affect Treatment Decisions
November 23rd 2015A new method to elucidate the clonal relationship between tumors used tissues and clinical details from patients with contralateral breast cancer, and for the first time, next-generation sequencing.
Read More
Dr. Julie Gralow on the Importance of Genetic Testing for Breast Cancer
October 26th 2015Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, talks about the importance of women knowing which genetic tests they�ve previously had done for breast cancer.
Watch
Baseline Analysis of CTC Enumeration and AR Localization in Men With mCRPC
July 7th 2015Scott T. Tagawa, MD, MS, medical director, Genitourinary Oncology Research Program, associate professor, Clinical Medicine and Urology, Weill Cornell Medical College, discusses the baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC).
Watch
Significance of the NCI Molecular Analysis for Therapy Choice Program
June 10th 2015Jonathan C. Trent, MD, PhD, professor of medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Health System, gives an overview of the NCI Molecular Analysis for Therapy Choice Program (MATCH).
Read More
A Little STING May Enhance the Immune System Against Cancer
April 25th 2015Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Read More
Tumor-Only Gene Sequencing May Expose Half of Cancer Patients to Unsuitable Treatments
April 15th 2015Almost half of patients with cancer who receive genetic testing may be given information that leads to unsuitable targeted treatments, according to researchers from Johns Hopkins Kimmel Cancer Center.
Read More
Whole-Genome Sequencing Identifies New Targets in Pancreatic Cancer
April 14th 2015A research team led by investigators at the University of Texas Southwestern Medical Center in Dallas has published a study in Nature Communications identifying several new genetic mutations in pancreatic ductal adenocarcinoma.
Read More
Varmus Leaving NCI to Move Precision Medicine in Oncology Forward on Other Fronts
March 7th 2015Harold Varmus, MD, may be stepping down as director of the National Cancer Institute (NCI) at the end of March, but in an interview with Targeted Oncology, he made it clear that he is not retiring.
Read More